Nyumbani › Burkitt Lymphoma
Majaribio ya kliniki ya Burkitt Lymphoma yanayovutia washiriki nchini Marekani
Masomo 63 ya Burkitt Lymphoma yanavutia washiriki katika vituo vya Marekani nzima.
Miji yenye masomo mengi
- Houston, TXUtafiti 21
- Milwaukee, WIUtafiti 16
- Philadelphia, PAUtafiti 16
- New York City, NYUtafiti 14
- Chicago, ILUtafiti 14
- Cincinnati, OHUtafiti 12
- Atlanta, GAUtafiti 12
- Seattle, WAUtafiti 11
- Durham, NCUtafiti 10
- Boston, MAUtafiti 10
- Aurora, COUtafiti 10
- Los Angeles, CAUtafiti 10
- Kansas City, MOUtafiti 10
- Minneapolis, MNUtafiti 9
- Washington, DCUtafiti 9
- Orange, CAUtafiti 9
- Baldwin Park, CAUtafiti 9
- Buffalo, NYUtafiti 8
- Portland, ORUtafiti 8
- Columbus, OHUtafiti 8
- Baltimore, MDUtafiti 8
- Ann Arbor, MIUtafiti 8
- Nashville, TNUtafiti 8
- San Francisco, CAUtafiti 8
- Tampa, FLUtafiti 7
- Clifton, NJUtafiti 7
- Providence, RIUtafiti 7
- Dallas, TXUtafiti 7
- Oklahoma City, OKUtafiti 7
- Salt Lake City, UTUtafiti 7
- San Antonio, TXUtafiti 7
- Richmond, VAUtafiti 7
- Jacksonville, FLUtafiti 7
- Greenburgh, NYUtafiti 7
- Birmingham, ALUtafiti 7
- Grand Rapids, MIUtafiti 7
- Cleveland, OHUtafiti 7
- The Bronx, NYUtafiti 6
- Mountain View, CAUtafiti 6
- St. Petersburg, FLUtafiti 6
Kwa jimbo
- AlabamaUtafiti 7
- ArizonaUtafiti 7
- ArkansasUtafiti 5
- CaliforniaUtafiti 20
- ColoradoUtafiti 13
- ConnecticutUtafiti 7
- DelawareUtafiti 7
- FloridaUtafiti 15
- GeorgiaUtafiti 12
- HawaiiUtafiti 5
- IdahoUtafiti 6
- IllinoisUtafiti 14
- IndianaUtafiti 6
- IowaUtafiti 7
- KansasUtafiti 6
- KentuckyUtafiti 5
- LouisianaUtafiti 4
- MaineUtafiti 4
- MarylandUtafiti 11
- MassachusettsUtafiti 10
- MichiganUtafiti 10
- MinnesotaUtafiti 10
- MississippiUtafiti 4
- MissouriUtafiti 8
- NebraskaUtafiti 5
- NevadaUtafiti 6
- New HampshireUtafiti 4
- New JerseyUtafiti 8
- New MexicoUtafiti 3
- New YorkUtafiti 20
- North CarolinaUtafiti 13
- North DakotaUtafiti 5
- OhioUtafiti 17
- OklahomaUtafiti 7
- OregonUtafiti 8
- PennsylvaniaUtafiti 18
- Rhode IslandUtafiti 7
- South CarolinaUtafiti 5
- South DakotaUtafiti 5
- TennesseeUtafiti 10
- TexasUtafiti 24
- UtahUtafiti 7
- VermontUtafiti 3
- VirginiaUtafiti 7
- WashingtonUtafiti 11
- West VirginiaUtafiti 3
- Wilaya ya ColumbiaUtafiti 5
- WisconsinUtafiti 17
Masomo yaliyosasishwa hivi karibuni
Maandishi rasmi ya utafiti (Kiingereza)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
InaajiriHatua 2
366 Days – 46 Years · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
InaajiriHatua 3
Umri 18 hadi 39 · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT03150693Blinatumomab Consolidation in Real World
InaajiriUtafiti wa uchunguziWajitolea wenye afya wanakaribishwa
Umri 18 na zaidi · Jinsia zote · Imesasishwa 1 Okt 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
InaajiriUtafiti wa uchunguzi
Umri 0 hadi 38 · Jinsia zote · Imesasishwa 1 Okt 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
InaajiriHatua 1/2
Umri 3 hadi 39 · Jinsia zote · Imesasishwa 30 Sep 2026 · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 29 Sep 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
InaajiriHatua 1/2
Umri 18 hadi 120 · Jinsia zote · Imesasishwa 28 Sep 2026 · NCT03223610Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT06144606Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
InaajiriHatua 2
365 Days · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
InaajiriHatua 3
Umri 18 na zaidi · Jinsia zote · Imesasishwa 21 Sep 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
InaajiriHatua 3
Umri 1 na zaidi · Jinsia zote · Imesasishwa 17 Sep 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
InaajiriHatua 1/2
6 Months – 25 Years · Jinsia zote · Imesasishwa 17 Sep 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
InaajiriHatua 1
Umri 0 hadi 18 · Jinsia zote · Imesasishwa 16 Sep 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
InaajiriHatua 1/2
31 Days – 30 Years · Jinsia zote · Imesasishwa 14 Sep 2026 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
InaajiriHatua 2
Umri 1 hadi 30 · Jinsia zote · Imesasishwa 1 Sep 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
InaajiriHatua 1
Umri 18 hadi 120 · Jinsia zote · Imesasishwa 25 Ago 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
InaajiriHatua 3
365 Days – 25 Years · Jinsia zote · Imesasishwa 25 Ago 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Inaajiri
Umri 18 na zaidi · Jinsia zote · Imesasishwa 19 Ago 2026 · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
InaajiriHatua 2
Umri 7 hadi 25 · Jinsia zote · Imesasishwa 19 Ago 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
InaajiriHatua 1/2
Umri 12 na zaidi · Jinsia zote · Imesasishwa 19 Ago 2026 · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 12 Ago 2026 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 10 Ago 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
InaajiriHatua 2
Umri 15 na zaidi · Jinsia zote · Imesasishwa 10 Ago 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
InaajiriHatua 1/2
Umri 13 hadi 90 · Jinsia zote · Imesasishwa 6 Ago 2026 · NCT06533579Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.